Forbion Growth Opportunities Fund I Cooperatief U.A.'s Form 4 filing
enGene Therapeutics Inc. (ENGN) · filed Oct 18, 2024
- Accession no.
- 0000950170-24-115607
- Filed
- Oct 18, 2024, 4:15 PM ET
- Trade date
- Dec 27, 2023-Oct 8, 2024
- Filing delay
- 296 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 13 non-derivative transactions and 0 derivative transactions. Open-market purchases total $3.01M. It was filed 296 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Forbion Growth Opportunities Fund I Cooperatief U.A.CIK 0001911047 | 10% Owner |
| Forbion Growth Management B.V.CIK 0001918318 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 27, 2023 | Common Shares | PPurchaseAcquired | +2,750 | $7.17 | +$19,711.45 | 2,002,750 | Direct | |
| Dec 28, 2023 | Common Shares | PPurchaseAcquired | +5,050 | $7.69 | +$38,826.93 | 2,007,800 | Direct | |
| Dec 29, 2023 | Common Shares | PPurchaseAcquired | +400 | $8.30 | +$3,320 | 2,008,200 | Direct | |
| Dec 29, 2023 | Common Shares | PPurchaseAcquired | +9,620 | $9.09 | +$87,450.61 | 2,017,820 | Direct | |
| Sep 27, 2024 | Common Shares | PPurchaseAcquired | +38,396 | $5.94 | +$228,010.81 | 2,056,216 | Direct | |
| Sep 27, 2024 | Common Shares | PPurchaseAcquired | +3,243 | $6.38 | +$20,688.39 | 2,059,459 | Direct | |
| Sep 30, 2024 | Common Shares | PPurchaseAcquired | +341,332 | $6.34 | +$2,163,362.22 | 2,400,791 | Direct | |
| Oct 1, 2024 | Common Shares | PPurchaseAcquired | +35,279 | $6.44 | +$227,157.95 | 2,436,070 | Direct | |
| Oct 2, 2024 | Common Shares | PPurchaseAcquired | +10,153 | $6.37 | +$64,696.95 | 2,446,223 | Direct | |
| Oct 3, 2024 | Common Shares | PPurchaseAcquired | +5,769 | $6.48 | +$37,396.97 | 2,451,992 | Direct | |
| Oct 4, 2024 | Common Shares | PPurchaseAcquired | +5,997 | $6.54 | +$39,241.97 | 2,457,989 | Direct | |
| Oct 7, 2024 | Common Shares | PPurchaseAcquired | +11,844 | $6.55 | +$77,530.82 | 2,469,833 | Direct | |
| Oct 8, 2024 | Common Shares | PPurchaseAcquired | +800 | $6.60 | +$5,278.48 | 2,470,633 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.